Emerald Clinics Ltd (ASX:EMD) has signed new agreements that will enhance its data capture technology platform and support the launch of a new digital health and clinical monitoring service called ‘Sentinel Plus’.
The company secured an agreement with artificial intelligence (AI) technology company, Binah.ai, to incorporate Binah’s world-leading smartphone technology into Emerald’s Real-World Evidence (RWE) engine.
In addition, Emerald has been engaged by Linear Clinical Research to support the remote evaluation of more than 150 healthy volunteer trial participants over a two-year period for a Phase 1 COVID-19 vaccine study.
Chief executive officer Dr Michael Winlo said: “These collaborations greatly extend the reach and impact of Emerald’s digital health Real-World Evidence engine that we have built over several years as well as expand our commercial offerings with Sentinel Plus.”
Dr Winlo said: “Our RWE engine is the core of Emerald and it learns from each individual patient that we monitor or treat.
“The platform also provides an evidence-based health monitoring service for businesses of all shapes and sizes and produces relevant, accurate and actionable health information.
“It will empower businesses to get back to work with a greater level of comfort, knowing that proactive monitoring measures are in place to protect the health and safety of their workforce.
“We anticipate that this technology will greatly support workforce culture, productivity and overall economic performance.”
The Binah.ai technology harnesses video and AI to support the capture of vital signs in a completely contactless manner by measuring the change in colour (micro-blushes) of the skin, pixel by pixel, in less than a minute.
Vital signs (such as heart rate and blood oxygen levels) provide clinically relevant data but are often difficult to obtain from patients remotely.
Further testing and validation of the Binah technology is planned in the coming month to integrate the Binah.ai technology with Emerald’s current RWE platform and, if successful, it will be able to capture and provide live reports on vital signs measurements using just the camera on a user’s mobile phone.
No other hardware (such as pulse oximeters or heart rate monitors) are required.
Emerald has licensed the Binah.ai technology for a fee of US$100,000 and has acquired the software developer kit to enable multiple applications.
Sentinel Plus potential
Subject to successful validation, Emerald is also targeting other potential customers for Sentinel Plus in anticipation of demand for a clinician-monitored service for remote health monitoring.
Organisations are reviewing a range of tools to enable monitoring of employees and students as they return to work and school, ranging from paper-driven surveys to integrated software tools like Sentinel Plus.
The company is confident that the ability to use mobile phones instead of costly and scarce hardware to capture vital signs and symptom information, provides an opportunity to scale remote care in a patient-friendly and cost-effective manner.
COVID-19 vaccine trial
The company has been engaged by Linear Clinical Research to support a two-year Phase 1 COVID-19 vaccine study.
Emerald will be paid a monthly retainer of $5,000 per month as well as separate consultation and data management fees for each required clinical review on a per-patient basis.
This Linear Agreement is subject to a review after an initial 3-month period and the study is scheduled to continue through to December 2022.
The company has been using its current RWE platform for COVID symptom monitoring across its patient population since April and plans to utilise the Binah.ai technology as part of this monitoring service.
Dr Winlo is also a director of Linear Clinical Research.